Introduction
Patients with erectile dysfunction (ED) prefer the least invasive form of therapy. 1 Two effective medical treatments for ED of various aetiologies include intracavernosal (IC) injection therapy with vasoactive agents (eg, prostaglandin E 1 (PGE 1 ), papaverine, and phentolamine) 2, 3 and oral therapy with phosphodiesterase type 5 inhibitors, sildenafil citrate (VIAGRA s ) being the first in the class. 4, 5 Despite its efficacy, IC PGE 1 therapy is associated with patient-initiated discontinuation rates as high as 60%. [6] [7] [8] [9] High discontinuation rates with IC vasoactive agents are attributable to a number of reasons, including penile pain and other complications of injection therapy, dislike of or difficulty with self-injection, fear of needles, poor response, change to alternate therapy, and lack of sexual spontaneity. [10] [11] [12] In contrast, in a large (n ¼ 979) 3-y extension study of sildenafil, in which most patients were receiving 100-mg doses, only 6.7% of patients discontinued for treatment-related reasons: 5.7% because of insufficient response and 1% because of treatment-related adverse events. 13 The present study was conducted at multiple centres in a clinical practice setting to evaluate the success rate and treatment satisfaction when patients with ED were switched from successful PGE 1 injection therapy to oral sildenafil therapy. Primary efficacy outcomes and safety were reported previously; a successful switch was defined as a patient having an Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) score after sildenafil treatment equal to or greater than the EDITS score after PGE 1 . 14 By that definition, 69% of patients successfully changed from IC PGE 1 to oral sildenafil.
14 Secondary outcomes are reported here, including (1) individual items of the EDITS questionnaire, which assesses patients' attitudes about treatment effectiveness, side effects, ease of use, naturalness of erections, and impact on partner, 15 and (2) factors of potential prognostic value in predicting treatment satisfaction after switching from IC PGE 1 therapy to sildenafil.
Patients and methods
Methodological details of this 16-week, open-label study conducted at 16 centres in France and Italy were reported previously. 14 In brief, patients with ED who were Z18 y of age, in a Z6-month stable relationship with a female partner, and using IC PGE 1 injection therapy (stable dose of r20 mg for 43 months), were treated for 12 weeks with sildenafil, initiated at a 50-mg dose and adjusted to 25 or 100 mg based on treatment response and tolerability. Sildenafil treatment was preceded by a 4-week runin phase during which IC PGE 1 therapy was continued, and by a 48-h PGE 1 washout period. Patients with at least 1 assessment after week 0 and who received at least 1 dose of sildenafil were included in the intent-to-treat analyses. The week-12 value was defined as the last post-baseline value recorded on or before week 12 (last observation carried forward). All patients signed informed consent, the study was conducted in compliance with ethical committee regulations, and the protocol was approved by the local institutional review boards.
At the end of the PGE 1 treatment phase (week 0) and after sildenafil treatment (week 12), patients completed the 11-item EDITS questionnaire, and their partners completed an abbreviated 5-item version of the EDITS questionnaire. Each EDITS item was scored from 0 to 4, with higher scores indicating greater treatment satisfaction. The mean EDITS questionnaire score was multiplied by 25, yielding a standardized EDITS index of treatment satisfaction score, ranging from 0 (low satisfaction) to 100 (extremely high satisfaction). For patients and their partners, paired Student's t-test was used to analyse the difference in EDITS scores between the end of PGE 1 therapy (week 0) and the end of sildenafil therapy (week 12). Pearson's correlation coefficients were determined to examine the relationship between patient and partner score differences.
Efficacy outcomes were analysed after stratification by patient age, aetiology of ED as stated by the investigators, duration of ED, smoking status, and baseline dose of IC PGE 1 . In addition to the EDITS index, outcomes analysed at the end of the PGE 1 treatment phase (week 0) and after sildenafil treatment (week 12) were a global efficacy question (GEQ, 'Has the treatment you have been taking over the past 4 weeks improved your erections compared to no treatment at all?'), the erectile function (EF) domain score from the validated International Index of Erectile Function (IIEF), 16 the percentage of successful attempts at intercourse (documented in a patient event log), and the percentage of patients successfully switching to sildenafil. A successful switch was defined as a patient having an EDITS score after sildenafil treatment equal to or greater than the EDITS score after PGE 1 . Statistical significance of between-group differences was determined using paired t-tests. There was no Bonferroni's correction for the multiple t-tests.
Results
Among the 176 patients who switched from IC PGE 1 to oral sildenafil, the mean age was 56 y (range 23-80), mean duration of ED was 4. 3 y (range 0.5-24.1) and of IC PGE 1 therapy was 21 months (range 2-97), and the mean dose of IC PGE 1 was 13 mg (range 2-20). 14 This is comparable to IC PGE 1 doses reported previously. 17, 18 The final sildenafil dose was 25 mg in 2% of patients, 50 mg in 30%, and 100 mg in 69%.
14 In total, 32 partners agreed to participate.
Analysis of individual EDITS items
Mean patient scores after sildenafil compared with scores after IC PGE 1 therapy showed significant differences in favour of sildenafil for EDITS Q1 (overall satisfaction, 2.88 vs 2.58; Po0.01), Q3 (likely to continue, 3.26 vs 2.67; Po0.001), Q4 (ease of use, 3.65 vs 2.51; Po0.001), Q9 (partner's desire to continue treatment, 2.79 vs 2.54; Po0.05), and Q10 (naturalness of erectile process, 2.04 vs 1.76; Po0.001). For the remaining EDITS questions, the two therapies were comparable (P ¼ NS), including patient expectations (Q2), satisfaction with onset (Q5), duration of action (Q6), confidence in ability to engage in sexual activity (Q7), patient-rated partner satisfaction (Q8), and naturalness of erection (Q11).
Mean partner scores after sildenafil compared with scores after PGE 1 therapy showed a significant difference in favour of sildenafil for partner EDITS Q1 (overall satisfaction, 2.81 vs 2.34; Po0.05). The two therapies were comparable (P ¼ NS) in satisfying partner expectations (Q2), sense of being sexually desirable (Q3), satisfaction with the duration of action (Q4), and wish to have the patient continue treatment (Q5).
Pearson's correlation analysis showed a high degree of correlation between responses for matched patients/partners in overall satisfaction (Q1/Q1, r ¼ 0.68), meeting expectations (Q2/Q2, r ¼ 0.75), duration of action (Q6/Q4, r ¼ 0.73), and wish to continue treatment (Q9/Q5, r ¼ 0.82). There was a moderate correlation between patient confidence 
Stratification of efficacy by potentially prognostic variables
The improvement in mean EDITS index of treatment satisfaction scores between baseline (PGE 1 therapy) and sildenafil therapy was statistically significant regardless of smoking history and among patients who were (1) o65 y, (2) had ED of psychogenic or mixed aetiology, (3) had ED for 42 y, or (4) were using o20 mg IC PGE 1 at baseline (Figure 1 , Table 1 ). Patients o50 y and those with ED of psychogenic origin also had significantly improved mean scores from baseline for the mean IIEF EF domain (Table 1) . However, patients with ED of organic origin had a deterioration of mean scores from baseline for the mean EF domain.
A significantly higher percentage of attempts at sexual intercourse were successful with PGE 1 than with sildenafil, regardless of the duration of ED, in nonsmokers, in patients 50 y of age or older, with ED of organic origin, or using a baseline dose of PGE 1 Z10 mg (Table 1 ). The percentage of successful attempts in patients using sildenafil decreased with increasing age, duration of ED, and baseline dose of PGE 1 , and was lower in patients who had never smoked or had ED of organic aetiology. Nevertheless, during sildenafil therapy most attempts at sexual intercourse were successful (range 59-87% among the various stratified groups) and most patients responded affirmatively to the GEQ (70-98% among the various stratified groups), regardless of age, aetiology, ED duration, smoking status, or baseline PGE 1 dose.
Discussion
The attrition rate for patients treated with IC PGE 1 is high, with 40% discontinuing during the first 3 months of treatment. 19 This study demonstrated that, among a group of patients who were sufficiently satisfied with IC PGE 1 therapy to have continued for at least 3 months (mean 21), overall treatment satisfaction was greater with subsequent oral sildenafil treatment. Patients were more satisfied with the ease of use and naturalness of the erectile process and were more likely to profess an intention to continue treatment and to believe their partner wished to continue treatment. The preference to continue sildenafil treatment is consistent with Hatzichristou et al, 20 who found that approximately 64% of men with ED responding to sildenafil treatment during a 3-month trial period preferred it to previous long-term IC injection therapy.
Patients receiving IC PGE 1 injection therapy reported a higher intercourse success rate (88.7%) than patients receiving oral sildenafil (73.3%). This is not surprising considering the mechanism of action of each agent, and that sexual stimulation is required for sildenafil to be effective. Interestingly, Figure 1 Mean improvement in EDITS index of treatment satisfaction score between intracavernosal PGE 1 (baseline) and oral sildenafil (week 12), stratified according to potentially prognostic variables. ED ¼ erectile dysfunction; s.e. ¼ standard error. *Po0.05, **Po0.01, or ***Po0.001 between treatments.
Satisfaction after PGE1 switch F Montorsi et al Inclusion criteria mandated that participants had been receiving IC PGE 1 injection therapy at a stable dose of p20 mg for >3 months. despite this higher intercourse success rate with PGE 1 , patients still preferred an oral medication for treatment of their ED. The noninvasiveness of sildenafil therapy was likely a major factor in patients' preference for sildenafil over PGE 1 therapy. For example, in a large efficacy trial (n ¼ 683), dislike of self-injection and difficulty with injection technique were reasons for discontinuation of IC PGE 1 therapy in 19 and 4%, respectively, of study patients over 6 months. 12 Tolerability may also have been a factor in the greater overall treatment satisfaction with sildenafil treatment than with IC PGE 1 treatment. Adverse effects of IC PGE 1 treatment include penile pain and bruising, scarring and nodules, and infections, 6 whereas adverse effects of sildenafil treatment are mild to moderate, consisting most frequently of transient headache, nasal congestion, dyspepsia, flushing, or abnormal vision. 21 Interestingly, in the current study, patients were no less satisfied with the rapidity of onset and duration of action of sildenafil than with IC PGE 1 and were equally confident in their ability to engage in sexual activity. This is consistent with similar efficacy of the two treatments in enabling patients to achieve and maintain erections of penetrative rigidity.
14 The current analysis also showed that partners were more satisfied with sildenafil than with IC PGE 1 and that there was a high degree of correlation between patient and partner satisfaction, confirming earlier reports. 22, 23 In our study, 42% of patients had organic ED, 34% had psychogenic ED, and 24% had mixed ED, which is comparable to previous studies that also showed sildenafil to be effective in men with ED of organic, psychogenic, or mixed causes. 4, 5 Organic causes of ED tend to be associated with greater ED severity, and patients with less severe ED, such as psychogenic ED, tend to have better treatment outcomes. 24, 25 Indeed, satisfaction with treatment, as defined by the EDITS questionnaire, was greater for sildenafil than IC PGE 1 in younger patients (o65 y), in patients with ED of psychogenic or mixed aetiology, in patients who had ED for 42 y, and in patients using o20 mg IC PGE 1 at baseline. Collectively, these data suggest that sildenafil may be a more satisfactory treatment in less severe cases of ED. This would not be unexpected given that the PGE 1 injections do not require sexual stimulation.
The relation between treatment satisfaction associated with age and ED aetiology was analogous in the IIEF efficacy outcomes. The apparent decreased response to and satisfaction with sildenafil therapy with increasing age may reflect age-related increases in the level of stimulus required to elicit penile erection. 26 Results of experiments in rat models suggest that increased penile stimulus thresholds may be related to age-associated reduction in nitric oxide (NO) production in the corpus cavernosum. 27, 28 This could affect the response to sildenafil, which acts through the NO/cGMP pathway. 29 Nevertheless, 64% of patients aged 50 y or older successfully switched from IC PGE 1 to oral sildenafil, and 76% of patients aged 65 y or older reported improvement of their erections with sildenafil therapy compared with no treatment.
As the recommended dose of IC PGE 1 ranges from 10 to 60 mg, 30 a potential limitation of the current study may be the maximum allowable dose of 20 mg. However, PGE 1 doses ranging from 2.5 to 20 mg were shown to be superior to placebo in a dose-response study of 296 men, 12 and 20 mg was the largest maintenance dose required in a study to identify factors influencing dosage. 30 Combined with its ease of use and its wellestablished efficacy and safety profile, 21 evidence from the current study suggests that oral sildenafil is an advance in the treatment of ED. Greater patient satisfaction, less invasiveness, and lower discontinuation rates argue in favour of recommending sildenafil as first-line therapy for treatment of ED in the primary care setting.
